Platelet-to-high-density lipoprotein cholesterol ratio as a potential mediator in the obesity-chronic kidney disease association among hypertensive patients.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-6049 (Electronic) Linking ISSN: 0886022X NLM ISO Abbreviation: Ren Fail Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: New York, N.Y. : M. Dekker, c1987-

Obesity*/blood ; Obesity*/complications ; Obesity*/epidemiology ; Renal Insufficiency, Chronic*/blood ; Renal Insufficiency, Chronic*/epidemiology ; Renal Insufficiency, Chronic*/etiology ; Hypertension*/blood ; Hypertension*/complications ; Hypertension*/epidemiology ; Cholesterol, HDL*/blood ; Blood Platelets*; Biomarkers/blood ; Humans ; Male ; Female ; Middle Aged ; Nutrition Surveys ; Adult ; Aged ; Cross-Sectional Studies ; Body Mass Index ; Risk Factors ; Waist Circumference

This study investigated the relationship between the platelet-to-high-density lipoprotein cholesterol ratio (PHR) and chronic kidney disease (CKD) in a hypertensive population, exploring its mediating role in the obesity-CKD association. Using data from the National Health and Nutrition Examination Survey (NHANES) 2009-2018 on 10,467 hypertensive adults, we observed a complex association. Overall, PHR was positively correlated with CKD (odds ratio [OR] = 1.08, 95% CI: 1.05-1.14). However, the relationship was nonlinear and U-shaped, with an inflection point at a PHR Z-score of -0.32 (PHR = 166). Below this point, the association was negative (OR = 0.78, 95% CI: 0.65-0.91), whereas above it, the association was strongly positive (OR = 1.24, 95% CI: 1.15-1.36), particularly among individuals with obesity (BMI ≥ 30 kg/m²). Furthermore, PHR significantly mediated the relationship between obesity and CKD, accounting for 21.46% of the effect from BMI and 18.01% from waist circumference. In conclusion, PHR exhibits a U-shaped relationship with CKD in hypertensive individuals, most prominently in those with obesity, and may serve as an accessible biomarker of obesity-related inflammation for CKD risk stratification.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):28-36. (PMID: 25470014)
Eur Heart J. 2021 Dec 14;42(47):4791-4806. (PMID: 34472586)
Int J Chron Obstruct Pulmon Dis. 2024 Oct 23;19:2321-2332. (PMID: 39465032)
Eur J Prev Cardiol. 2020 Oct;27(15):1606-1616. (PMID: 31840535)
BMC Public Health. 2023 Dec 1;23(1):2388. (PMID: 38041010)
Kidney Int. 2021 Oct;100(4S):S1-S276. (PMID: 34556256)
Front Endocrinol (Lausanne). 2024 Feb 21;15:1289553. (PMID: 38449847)
Cardiovasc Res. 2014 Aug 1;103(3):362-71. (PMID: 24891399)
Nat Rev Cardiol. 2024 Jun;21(6):396-416. (PMID: 38172242)
Diabetes Metab J. 2022 Sep;46(5):747-755. (PMID: 35350091)
Int J Mol Sci. 2018 Apr 02;19(4):. (PMID: 29614819)
Int J Mol Sci. 2020 Jan 17;21(2):. (PMID: 31963445)
Lipids Health Dis. 2023 Aug 11;22(1):130. (PMID: 37568178)
Hypertension. 2012 Feb;59(2):324-30. (PMID: 22146512)
Ren Fail. 2024 Dec;46(2):2415514. (PMID: 39412048)
Psychooncology. 2025 Jan;34(1):e70064. (PMID: 39794295)
Curr Atheroscler Rep. 2023 Sep;25(9):605-612. (PMID: 37594602)
Pflugers Arch. 2024 Nov;476(11):1677-1691. (PMID: 39215834)
Kidney Int Suppl (2011). 2022 Apr;12(1):7-11. (PMID: 35529086)
Eur Heart J. 2017 Aug 21;38(32):2478-2486. (PMID: 28419274)
Ren Fail. 2024 Dec;46(2):2396459. (PMID: 39311633)
Cardiovasc Res. 2021 Jan 21;117(2):411-422. (PMID: 32666079)
N Engl J Med. 2021 Nov 4;385(19):1737-1749. (PMID: 34554658)
Med J Islam Repub Iran. 2021 Jul 01;35:85. (PMID: 34291009)
BMC Cardiovasc Disord. 2022 Jan 28;22(1):18. (PMID: 35090385)
Sci Rep. 2024 Jul 8;14(1):15641. (PMID: 38977840)
Clin Nutr. 2024 Oct;43(10):2289-2295. (PMID: 39217844)
Front Endocrinol (Lausanne). 2024 Feb 22;15:1329256. (PMID: 38455650)
J Am Coll Cardiol. 2003 Jun 4;41(11):1972-82. (PMID: 12798568)
Lipids Health Dis. 2024 Apr 24;23(1):121. (PMID: 38659020)
Diabetes Metab Res Rev. 2021 Sep;37(6):e3403. (PMID: 32886844)
Lipids Health Dis. 2024 Oct 26;23(1):346. (PMID: 39462374)
J Inflamm Res. 2024 May 06;17:2731-2744. (PMID: 38737110)
Med Clin North Am. 2017 Jan;101(1):169-193. (PMID: 27884227)
Circulation. 2000 Apr 25;101(16):1907-12. (PMID: 10779455)
Hypertension. 2020 Jun;75(6):1334-1357. (PMID: 32370572)
Hypertension. 2017 Oct;70(4):660-667. (PMID: 28784646)
Am J Physiol Endocrinol Metab. 2023 Jan 1;324(1):E24-E41. (PMID: 36383637)
Kidney Res Clin Pract. 2019 Sep 30;38(3):365-372. (PMID: 31357262)
Cardiovasc Diabetol. 2009 Sep 15;8:51. (PMID: 19754934)
Neuroimage Clin. 2015 Aug 18;9:164-75. (PMID: 27330979)
Can J Cardiol. 2020 May;36(5):635-647. (PMID: 32389337)
Front Endocrinol (Lausanne). 2024 Jul 29;15:1402336. (PMID: 39149124)
N Engl J Med. 2017 Sep 21;377(12):1119-1131. (PMID: 28845751)
J Clin Med. 2024 Feb 27;13(5):. (PMID: 38592161)
Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
J Immunol Res. 2018 Sep 6;2018:2180373. (PMID: 30271792)
Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):180-6. (PMID: 17951323)
Nat Med. 2001 Jul;7(7):853-7. (PMID: 11433352)
Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s03-s09. (PMID: 31939529)
Atheroscler Plus. 2023 Apr 18;52:9-17. (PMID: 37193017)
Arterioscler Thromb Vasc Biol. 2000 Feb;20(2):353-9. (PMID: 10669630)
Circ Res. 2022 Aug 5;131(4):328-344. (PMID: 35862128)
Front Cardiovasc Med. 2019 Feb 28;6:16. (PMID: 30873416)
Healthcare (Basel). 2024 Aug 03;12(15):. (PMID: 39120243)
Am J Nephrol. 2009;30(2):140-6. (PMID: 19299892)
Diabetes Care. 2023 Feb 1;46(2):425-433. (PMID: 36490263)
Am J Kidney Dis. 2021 Mar;77(3):427-439. (PMID: 33075388)

Keywords: Chronic kidney disease; NHANES; hypertension; obesity; platelet-to-high-density lipoprotein ratio

0 (Cholesterol, HDL)
0 (Biomarkers)

Date Created: 20251216 Date Completed: 20251216 Latest Revision: 20251219

20260130

PMC12710265

10.1080/0886022X.2025.2598937

41399132